文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

西非与东南亚国家治疗前HIV整合酶抑制剂耐药流行率

Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

研究利用2015至2016年采集的样本生成HIV整合酶序列,评估西非与东南亚地区治疗前整合酶链转移抑制剂(INSTI)耐药频率。共获得353条整合酶序列,INSTI治疗前耐药总体频率为1.1%(4/353),各国范围0%至6.3%。任何药物类别治疗前耐药频率高达17.9%(95%CI:13.9%-22.3%),主要与非核苷类逆转录酶抑制剂(NNRTI)高耐药水平9.7%及核苷类逆转录酶抑制剂(NRTI)中等耐药水平5.3%相关。

要点

  • INSTI治疗前耐药总体频率低,为1.1%(4/353),各国范围0%至6.3%。
  • 任何药物类别治疗前耐药频率高达17.9%(95%CI:13.9%-22.3%)。
  • NNRTI治疗前耐药水平高(9.7%),NRTI为中等水平(5.3%)。

核心结论

  • 结果支持近期在低收入和中等收入国家引入INSTI以改善治疗结局,同时强调需采取有效行动防止该药物类别耐药不受控制地出现。

研究设计与样本

  • 利用2015至2016年采集、此前用于评估蛋白酶抑制剂(PI)、NRTI和NNRTI耐药的样本,生成HIV整合酶序列。
  • 使用Stanford和ANRS算法识别相关INSTI治疗前耐药突变。
  • 共生成353条整合酶序列。

主要发现

  • INSTI治疗前耐药总体频率为1.1%(4/353),按国家范围为0%至6.3%。
  • 任何药物类别治疗前耐药频率为17.9%(95%CI:13.9%-22.3%)。
  • NNRTI治疗前耐药水平高,为9.7%。
  • NRTI治疗前耐药为中等水平,为5.3%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Integrase strand transfer inhibitors (INSTIs) have been recently recommended as the preferred first-line option for antiretroviral treatment initiators in low- and middle-income countries (LMICs) in response to the growing circulation of resistant HIV to non-nucleoside reverse transcriptase inhibitors (NNRTIs). In this study, we estimated the frequency of pretreatment drug resistance (PDR) to INSTIs in West Africa and Southeast Asia. MATERIALS AND METHODS: Using samples collected from 2015 to 2016, and previously used to assessed PI, NRTI and NNRTI resistance, we generated HIV integrase sequences and identified relevant INSTI PDR mutations using the Stanford and ANRS algorithms. RESULTS: We generated 353 integrase sequences. INSTI PDR frequency was low, 1.1% (4/353) overall, ranging from 0% to 6.3% according to country. However, frequency of PDR to any drug class was very high, 17.9% (95% CI: 13.9%-22.3%), and mostly associated with a high level of NNRTI PDR, 9.7%, and a moderate level of NRTI PDR, 5.3%. CONCLUSIONS: Our results support the recent introduction of INSTIs in LMICs to improve treatment outcome in these settings, but also stress the need for effective actions to prevent uncontrolled emergence of drug resistance to this drug class.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Aghokeng AF, Ngo-Giang-Huong N, Huynh THK, et al. Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries. J Antimicrob Chemother. 2024. PMID: 38546752. doi:10.1093/jac/dkae087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。